Agios Pharmaceuticals is a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals was formerly known as CANCER METABOLISM THERAPEUTICS And changed its name to Agios Pharmaceuticals In April 2008. The company is based in Cambridge, Massachusetts.

Inari Medical is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. They are focused on treating venous thromboembolism and improving the quality of life of patients suffering from this disease by safely and effectively removing blood clots. It has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The ClotTriever system is 510(k)-cleared by the FDA for thrombectomy in the peripheral vessels and is used to treat patients suffering from deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism. The company was founded in 2011 and is headquartered in Irvine, California.

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

Gyeongbuk Institute for Bio Industry is a private company headquartered in Andong, the South Korea. The firm operates as research institute.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. It offers specialty pharmacy and laboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals. The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

Galaxy Therapeutics provides neurovascular devices that increase the rate of curing the disease and offer easy deployment, fluoroscopic visualization, and treatment for shallow or large aneurysms, enabling patients to avail improved medical treatment.

Mercator MedSystems’ mission is to become a global leader in interventional, site-specific delivery of therapeutics that improve patient outcomes in vascular disease, oncology, and regenerative medicine. The 15th and 16th Centuries marked the beginning of the Age of Exploration, a time of bold action, vast territorial expansion and profound intellectual discovery. Gerardus Mercator (1512-1594), a mathematician and cartographer, played a key role in these ventures. He was as important to navigation as Copernicus was to astronomy. He perfected a map projection that was the first to represent the spherical surface of the earth in two dimensions. The Mercator Projection effectively transformed navigation, making it possible for ships to deliver cargo safely to any port on the globe. Inspired by the spirit of our namesake, Mercator MedSystems has developed a medical technology that enables the safe and accurate delivery of therapies anywhere in the body, ranging from drugs for diseased blood vessels, to stem cells that regenerate ailing tissues and organs. We believe this breakthrough will allow the expansion of medical therapy and stimulate profound intellectual exploration into new treatments for disease. We invite you to explore our web site, our technology and products, and to follow our progress to a new world of therapeutic delivery.

Silence Therapeutics GmbH, a subsidiary of Silence Therapeutics Plc, is a German company located in Berlin that operates biotechnology company to develops RNAi-based drugs. The firm was founded in 2014.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Bolt Medical, Inc. is a private company headquartered in Carlsbad, CA. The firm supplies medical equipment. Keegan Harper has been the CEO since 2019.

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare.

Thrombolex designs, develops, manufactures, and distributes innovative endovascular catheters. The company's mission is to create innovative endovascular catheters for use in the treatment of patients with arterial and venous thromboembolic (A+VTE) conditions. It allows for the selective infusion of the physician, specified fluids, including thrombolytics, into precise locations in the patient’s peripheral vasculature. Thereby treating the thrombus more efficiently in less time, using lower doses of thrombolytic drugs, thus reducing costs. Thrombolex was founded in 2016 by Michael J. Cerminaro.

Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.

Kowa Co., Ltd. engages in trading of textiles, machinery, and construction materials. The company also manufactures and sells medicines, medical equipment, and energy saving products. It operates through the following business divisions: Pharmaceutical, Medical Device, Foods, General Trading, Lifestyle Business, and Hospitality. The company was founded on December 25, 1894 and is headquartered in Nagoya, Japan.

Schering Corp. manufactures pharmaceutical products. It offers products in the areas of allergy and respiratory, anti-infectives, foot care, hepatitis, skin disorders, and sun care. It is a subsidiary of Schering-Plough Corp. The company is headquartered in Kenilworth, NY.